• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » BARDA funds development of five drugs to protect against radiation

BARDA funds development of five drugs to protect against radiation

October 5, 2011 By MassDevice

BARDA funds development of five drugs to protect against radiation

WASHINGTON–(BUSINESS WIRE)–The development of five new drugs to treat injuries associated with acute radiation syndrome will move forward under contracts awarded by the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA).

“These contracts support development of products that have the potential to address urgent public health requirements for radiation medical countermeasures while also meeting other unmet medical needs”
Acute radiation syndrome is caused by exposure to high doses of damaging (ionizing) radiation. ARS includes injuries to multiple organs, hemorrhaging, infection, and suppression of the immune system’s ability to fight organisms that cause infection.

Because no products are licensed to treat any aspect of acute radiation syndrome, BARDA is supporting the development of products to treat bone marrow, gastrointestinal, lung, and skin injury caused by radiation. BARDA expects to expand this list to include products to treat the thermal burns that might be caused by a nuclear detonation.

Today’s contracts total $56.3 million for development of products that potentially could treat bone marrow and gastrointestinal injuries from high levels of radiation, such as after denotation of an improvised nuclear device. Bone marrow and gastrointestinal injuries are expected to account for the majority of radiation-related deaths after a nuclear denotation.

The contracts were awarded to Neumedicines Inc. of Pasadena, Calif., RxBio Inc. of Johnson City, Tenn., the University of Arkansas for Medical Sciences of Little Rock, Ark., Araim Pharmaceuticals of Ossining, N.Y., and Cellerant Therapeutics of San Carlos, Calif.

“These contracts support development of products that have the potential to address urgent public health requirements for radiation medical countermeasures while also meeting other unmet medical needs,” said BARDA Director Robin Robinson, Ph.D. “For example, they may find day-to-day use in treating the side effects of cancer radiation treatment and chemotherapy. These advanced development contracts demonstrate what can be achieved by repurposing drugs with commercial potential to meet public health emergency requirements, and we would like to encourage other pharmaceutical companies and their collaborators to follow this approach.”

Today’s $17 million contract with Neumedicines Inc. will evaluate the safety and efficacy of a drug known as recombinant human interleukin-12 (rhuIL-12), or HemaMax, and will further develop manufacturing processes for HemaMax. Under a 2008 contract with BARDA, Neumedicines conducted proof-of-concept studies demonstrating that HemaMax mitigates bone marrow damage caused by damaging radiation. Today’s contract builds on that work.

Under a two-year, $15 million contract, RxBio Inc will study the efficacy of its drug Rx100, which may protect against radiation-induced gastrointestinal injury by interrupting programmed cell death, known as apoptosis. Preliminary data suggests that Rx100 can protect or mitigate injury and improve survival if administered up to 72 hours after deadly whole-body radiation exposure. The contract also supports development of manufacturing processes for the drug.

In a two-year, $4.5 million contract, UAMS will evaluate a drug, SOM230, developed by and provided under an agreement with Novartis. Novartis developed SOM230, or pasireotide, to treat a hormone disorder known as Cushing’s disease. Preliminary data suggest that the drug also may be useful in treating radiation injuries to the gastrointestinal system. Under the new contract, investigators at UAMS will generate data Novartis needs to submit a new drug application for possible Food and Drug Administration approval to use SOM230 to treat gastrointestinal injuries from radiation exposure. SOM230 appears to protect the intestine by reducing secretions from the pancreas that cross the damaged intestinal wall and exacerbate inflammation in the intestines.

Araim Pharmaceuticals won a two-year, $3.1 million contract to conduct studies of ARA 290 to evaluate whether the drug improves overall survival when the drug is administered 24 hours or longer after exposure to high doses of ionizing radiation. With anti-inflammatory properties and tissue-protective properties, the drug has shown promise in treating stroke, heart disease, and kidney failure. The studies under this contract are the next step in the drug development process and are needed before proceeding to clinical trials and pivotal efficacy studies.

In addition to these new contracts, BARDA today extended a 2010 contract with Cellerant Therapeutics for a second year and an additional $16.7 million. Under the contract, Cellerant will continue studies and manufacturing activities to further develop a new way to treat the illness known as neutropenia, an abnormally low number of white blood cells caused by exposure to high levels of ionizing radiation. Cellerant’s drug, called CLT-008, uses a kind of cells called myeloid progenitor cells, which can grow into any kind of blood cell the body needs.

CLT-008 is being developed to support and add to the patient’s own progenitor cells, providing protection for patients against life-threatening infections and hemorrhaging while their own bone marrow is recovering. CLT-008 could be used for other blood disorders and complications of cancer in which blood cells and platelets need to be replenished, so it also has promise as supportive therapy for patients receiving bone marrow or fetal cord blood transplants.

Today’s awards are part of a rapidly growing BARDA program to develop therapeutics and diagnostics for radiation injury. BARDA is seeking additional proposals for products that potentially could treat or illness and injury from acute radiation syndrome, as well as improved diagnostic tools to measure the radiation dose a person has absorbed after a nuclear denotation or radiation accident. Proposals are accepted through the Broad Agency Announcement BARDA-CBRN-BAA-11-100-SOL-00009 at www.fbo.gov.

BARDA, an agency within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services, provides a comprehensive integrated portfolio approach to the advanced research and development, innovation, acquisition, and manufacturing infrastructure for vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products for public health emergency threats. These threats include chemical, biological, radiological, and nuclear threats, pandemic influenza, and emerging infectious diseases.

For more information about BARDA and the advanced research and development of medical countermeasures visit www.phe.gov and www.medicalcountermeasures.gov. Contract opportunities and awards are announced at www.fbo.gov.

Note: All HHS press releases, fact sheets and other press materials are available at http://www.hhs.gov/news.

Contacts

HHS Press Office
202-690-6343

Recent Stories from U.S. Department of Health and Human Services

Filed Under: Uncategorized Tagged With: Dept. of Health & Human Services (HHS), Press Release

In case you missed it

  • Butterfly Network asks judge to dismiss Fujifilm Sonosite IP suit
  • Stereotaxis stock down amid cloudy outlook
  • BD, Labcorp collaborate on flow cytometry-based diagnostics
  • NeuroOne submits special FDA 510(k) application for Evo sEEG electrode
  • Si-Bone grows sales 15% in Q2
  • FDA approves second IDE study for CereVasc eShunt
  • Nuwellis posts Q2 sales beat
  • Avanos Medical updates full-year revenue guidance on mixed-bag Q2 results
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • Conformis rises on in-line Q2 results
  • ICU Medical stock sinks on Q2 misses, slashed 2022 guidance
  • Vicarious Surgical completes Beta 2 system design
  • Asensus Surgical says procedures up by more than a third in Q2
  • MRI pioneer Dr. Raymond Damadian dies at 86
  • BD makes tender offers for up to $500M of its debt
  • ViewRay moves HQ to Denver
  • Abbott is looking to address biases for cardiovascular patients

RSS From Medical Design & Outsourcing

  • Boston Scientific whistleblower launches corruption investigation
    Boston Scientific (NYSE:BSX) is investigating claims that the company violated the U.S. Foreign Corrupt Practices Act in Vietnam. Marlborough, Massachusetts–based Boston Scientific disclosed receipt of a whistleblower’s allegations in its latest filing with the Securities and Exchange Commission. “In March 2022, the company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam.… […]
  • 5 essential leadership lessons from Cathy Burzik for medtech’s next generation of women leaders
    Cathy Burzik, a seasoned senior executive in the healthcare industry, has successfully led major medical device, diagnostic, diagnostic imaging and life sciences businesses. Cathy Burzik, CFB Interests (as told to MedExecWomen co-founder Maria Shepherd) One key to being a successful women leader in MedTech: “Play nice, but play to win.” Cathy Burzik, who received a… […]
  • Stratasys plans to buy Covestro’s additive manufacturing business
    Stratasys (Nasdaq:SSYS) said today that it has a deal to purchase the additive manufacturing materials business of Covestro. The deal includes R&D facilities and activities, global development and sales teams across Europe, the U.S. and China, a portfolio of approximately 60 additive manufacturing materials, and hundreds of patents and patents pending, Stratasys said in a… […]
  • New implant design prevents scar tissue without drugs, MIT says
    Mechanically inflating and deflating an implantable device for 10 minutes a day prevents immune cells from building the scar tissue that has been a major obstacle for artificial pancreas researchers. That’s according to new findings from a team of MIT engineers who built mechanical deflection into a two-chambered, soft polyurethane device tested on mice. By… […]
  • Blue Spark’s TempTraq catches fevers faster. Fever prediction is next.
    Blue Spark Technologies developed the first wireless continuous temperature monitor patch, TempTraq, to enable faster fever detection than standard manual readings every four hours. Westlake, Ohio-based Blue Spark is now looking at fever prediction rather than just detecting them. The R&D team is working on developing an AI neural network model built on the company’s… […]
  • Harvard researchers plan to sell at-home, PCR-grade COVID testing system
    The Harvard University researchers who developed an ultrasensitive, PCR-grade nucleic acid detection technology plan to commercialize it as a portable COVID-19 test. Harvard Medical School professor Peng Yin, who also leads the Wyss Institute for Biologically Inspired Engineering’s Molecular Robotics Initiative, founded 3EO Health to sell the device. “In order to optimize the value of… […]
  • FDA reports sterilization challenge progress as EPA takes aim at EtO emissions
    The FDA offered an update on its efforts to make medical device sterilization safer as the EPA identified 23 U.S. facilities where use of ethylene oxide (EtO) presents a risk to communities. The FDA said it is similarly concerned about unsafe EtO emissions and highlighted work with the medical device industry to reduce EtO usage… […]
  • AdvaMed defends EtO facilities on EPA’s cancer risk list
    The Advanced Medical Technology Association (AdvaMed) today reacted to the EPA’s listing of commercial sterilization facilities causing elevated risks of cancer with a defense of the facilities and a call for more research. AdvaMed CEO and President Scott Whitaker said all of the listed facilities are in compliance with regulations and warned against closures. “The… […]
  • EPA flags high-cancer-risk EtO sterilization facilities across the country
    The EPA today identified nearly two dozen U.S. cities where commercial sterilizers using ethylene oxide (EtO) contribute to an elevated cancer risk for residents of surrounding communities. EtO is used on about 20 billion medical devices each year — or about half of all sterile medical devices —  and in some cases it’s the only… […]
  • New method of cardiac ablation used in first in-human trial for ventricular tachycardia
    A new cardiac ablation technique for patients with ventricular tachycardia (VT) has been used in its first in-human multicenter trial involving Mayo Clinic. The new process — needle ablation using in-catheter, heated, saline-enhanced, radio frequency (SERF) energy — creates lesion scars inside the heart muscle where life-threatening arrhythmias cause VT, Mayo Clinic said. Injecting heated saline… […]
  • AdvaMed pushes CMS for proposed TCET pathway rule this year
    The Advanced Medical Technology Association (AdvaMed) is asking the Centers for Medicare & Medicaid Services (CMS) to move fast on a new way to guarantee reimbursement for new medtech innovations. CMS repealed the Medicare Coverage of Innovative Technology (MCIT) program last year but promised to explore other options to improve the coverage process for access… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

August 5, 2022
DTW Medtronic's Greg Smith lays out supply chain strategies
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy